elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6B
Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6B
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect.
P2860
Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47106974-3B03C4BC-C295-41C1-A1E5-7E04BD64AA6B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b7e9c456b8d874d1780279c0029aa2b06e5e1fec
P2860
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.